Objective: To evaluate the efficacy of Poria-Polyporus anti-diarrhea oral liquor (PPAOL) in treating infantile rotavirus diarrhea. Methods: PPAOL was administered to treat 30 cases of infantile rotavirus diarrhea, the...Objective: To evaluate the efficacy of Poria-Polyporus anti-diarrhea oral liquor (PPAOL) in treating infantile rotavirus diarrhea. Methods: PPAOL was administered to treat 30 cases of infantile rotavirus diarrhea, the effect was observed and compared with that of Smecta. And human rotavirus RNA of patients was detected. Results: The effective rate of the PPAOL group was 83. 33 % and that of Smecta group was 90. 00 %.There was no significant difference between the effect of the two groups in respect of the duration of fever and diarrhea. Human rotavirus RNA showed positive result in 13 patients of PPAOL group and 19 in Smecta group.The duration of virus excretion in both groups was 2 ～7 days, which was much shorter than 9～ 21 days in the previous report. Conclusion: PPAOL is effective in treating infantile rotavirus diarrhea.展开更多
目的采用Meta分析方法评价双歧杆菌三联活菌制剂治疗轮状病毒肠炎的临床疗效。方法计算机检索中国知网、万方、维普、Pubmed、Embase和Web of Science数据库,检索时限均从建库至2015年12月,收集国内外应用双歧杆菌三联活菌制剂治疗轮状...目的采用Meta分析方法评价双歧杆菌三联活菌制剂治疗轮状病毒肠炎的临床疗效。方法计算机检索中国知网、万方、维普、Pubmed、Embase和Web of Science数据库,检索时限均从建库至2015年12月,收集国内外应用双歧杆菌三联活菌制剂治疗轮状病毒肠炎的所有随机对照试验(RCT)和前瞻性非随机对照试验(non-RCT)。按照纳入与排除标准选择文献、提取资料和评价纳入研究的方法学质量后,采用Cochrane协作网提供的Rev Man 5.2软件于2016-02-05进行Meta分析。结果检索文献无RCT研究,纳入21篇包含23个前瞻性non-RCT研究文献,合计3388例患儿,其中治疗组(对照组常规治疗+双歧杆菌三联活菌胶囊或散剂)1804例,对照组1584例。Meta分析结果显示:治疗组有效率高于对照组[OR=4.59,95%CI(3.69,5.70),P<0.01];治疗组止泻所用时间少于对照组[平均差(MD)=-1.39,95%CI(-2.24,-0.53),P=0.001];治疗组总治疗时间少于对照组[MD=-1.32,95%CI(-2.19,-0.45),P=0.003]。结论 Meta分析评价现有文献认为,双歧杆菌三联活菌胶囊或散剂与常规治疗措施联用可提高轮状病毒肠炎的总体疗效,并有效缩短止泻时间和总治疗时间。展开更多
文摘Objective: To evaluate the efficacy of Poria-Polyporus anti-diarrhea oral liquor (PPAOL) in treating infantile rotavirus diarrhea. Methods: PPAOL was administered to treat 30 cases of infantile rotavirus diarrhea, the effect was observed and compared with that of Smecta. And human rotavirus RNA of patients was detected. Results: The effective rate of the PPAOL group was 83. 33 % and that of Smecta group was 90. 00 %.There was no significant difference between the effect of the two groups in respect of the duration of fever and diarrhea. Human rotavirus RNA showed positive result in 13 patients of PPAOL group and 19 in Smecta group.The duration of virus excretion in both groups was 2 ～7 days, which was much shorter than 9～ 21 days in the previous report. Conclusion: PPAOL is effective in treating infantile rotavirus diarrhea.
文摘目的采用Meta分析方法评价双歧杆菌三联活菌制剂治疗轮状病毒肠炎的临床疗效。方法计算机检索中国知网、万方、维普、Pubmed、Embase和Web of Science数据库,检索时限均从建库至2015年12月,收集国内外应用双歧杆菌三联活菌制剂治疗轮状病毒肠炎的所有随机对照试验(RCT)和前瞻性非随机对照试验(non-RCT)。按照纳入与排除标准选择文献、提取资料和评价纳入研究的方法学质量后,采用Cochrane协作网提供的Rev Man 5.2软件于2016-02-05进行Meta分析。结果检索文献无RCT研究,纳入21篇包含23个前瞻性non-RCT研究文献,合计3388例患儿,其中治疗组(对照组常规治疗+双歧杆菌三联活菌胶囊或散剂)1804例,对照组1584例。Meta分析结果显示:治疗组有效率高于对照组[OR=4.59,95%CI(3.69,5.70),P<0.01];治疗组止泻所用时间少于对照组[平均差(MD)=-1.39,95%CI(-2.24,-0.53),P=0.001];治疗组总治疗时间少于对照组[MD=-1.32,95%CI(-2.19,-0.45),P=0.003]。结论 Meta分析评价现有文献认为,双歧杆菌三联活菌胶囊或散剂与常规治疗措施联用可提高轮状病毒肠炎的总体疗效,并有效缩短止泻时间和总治疗时间。
